Deutsch names Dowshen to head Zelnorm and Diovan business

Share this article:
Deutsch named Matt Dowshen to head the firm's business on Novartis' Zelnorm and Diovan. Dowshen, who joined from JWT New York, where he was senior partner/director-in-charge and co-leader of the DeBeers account, becomes SVP/group account director at Deutsch New York. In addition to the Novartis business, he will head the firm's IKEA account, reporting to Deutsch New York president Val DiFebo.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in News

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.